Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4-oxo-3-(3-oxo-1-phenylbutyl)chromen-2-olate
Drug ID BADD_D00005
Description Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Indications and Usage **Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
Marketing Status approved
ATC Code B01AA03
DrugBank ID DB00682
KEGG ID D00564; D08682; D01280
MeSH ID D014859
PubChem ID 23690541
TTD Drug ID D0E3OF
NDC Product Code 76282-328; 43353-054; 65162-764; 70518-2381; 76282-335; 70518-2382; 76282-333; 43353-023; 51407-345; 65162-762; 65162-765; 70518-2383; 71335-1786; 65162-763; 65162-767; 68788-8402; 71610-491; 71610-519; 50090-2646; 50090-5058; 70518-2717; 71610-458; 71610-462; 43353-029; 50090-2936; 51407-346; 65162-769; 43353-030; 65162-768; 70518-2394; 71610-448; 71610-490; 76282-330; 50090-2613; 51407-342; 65162-766; 70518-2816; 76282-329; 76282-331; 76282-334; 50090-3263; 71335-1824; 76282-332; 43353-021; 43353-028; 43353-053; 51407-343; 51407-344; 51407-347; 65162-761; 76282-327; 43353-033; 50090-2645
UNII 5Q7ZVV76EI
Synonyms Warfarin | 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one | Apo-Warfarin | Aldocumar | Gen-Warfarin | Warfant | Coumadin | Marevan | Warfarin Potassium | Potassium, Warfarin | Warfarin Sodium | Sodium, Warfarin | Coumadine | Tedicumar
Chemical Information
Molecular Formula C19H15LiO4
CAS Registry Number 81-81-2
SMILES [Li+].CC(=O)CC(C1=CC=CC=C1)C2=C(OC3=CC=CC=C3C2=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Asthenia08.01.01.001--Not Available
Body temperature increased13.15.01.001--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Coma17.02.09.001--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Epistaxis22.04.03.001; 24.07.01.005--
Fat embolism24.01.01.012; 12.01.08.003--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
The 1th Page    1 2 3    Next   Last    Total 3 Pages